BlackRock’s Virpax Pharmaceuticals, Inc. Common Stock VRPX Stock Holding History

BlackRock’s Portfolio VRPX Stock Details VRPX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-2	Closed	-$149	–	5445
2023 Q4	$149	Hold	2	–	–	﹤0.01%	5326
2023 Q3	$371	Hold	2	–	–	﹤0.01%	5364
2023 Q2	$501	Hold	2	–	–	﹤0.01%	5427
2023 Q1	$364	Hold	2	–	–	﹤0.01%	5496
2022 Q4	$289	Hold	2	–	–	﹤0.01%	5688
2022 Q3	$1K	Hold	2	–	–	﹤0.01%	5780
2022 Q2	$1K	Hold	2	–	–	﹤0.01%	5832
2022 Q1	$1K	Hold	2	–	–	﹤0.01%	5806
2021 Q4	$2K	Buy	+2	New	+$2.06K	﹤0.01%	5724

Other funds holding VRPX

TRCT

Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return

SRCM

Signature Resources Capital Management Newport Beach, California $254M AUM 26.72% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Parallel Advisors San Francisco, California $5.56B AUM 17.89% 1-Year Est. Return

BlackRock's VRPX Position: Q1 2024 in Review

BlackRock sold out of Virpax Pharmaceuticals, Inc. Common Stock (VRPX) in Q1 2024, closing a stake of 2 shares — an estimated $149 sold.

BlackRock first reported a position in VRPX in Q4 2021 and held it in 9 quarters. The position peaked at $2K in Q4 2021. 3 funds tracked by Wall St. Rank hold VRPX as of Q1 2024.

BlackRock reported no remaining Virpax Pharmaceuticals, Inc. Common Stock position as of Q1 2024 after selling out during the quarter.
BlackRock sold 2 Virpax Pharmaceuticals, Inc. Common Stock shares in Q1 2024, an estimated $149.
BlackRock first reported a position in Virpax Pharmaceuticals, Inc. Common Stock in Q4 2021 and held it in 9 quarters.
BlackRock's Virpax Pharmaceuticals, Inc. Common Stock position peaked at $2K in Q4 2021.
3 funds tracked by Wall St. Rank held Virpax Pharmaceuticals, Inc. Common Stock as of Q1 2024.

Based on BlackRock's 13F filing for Q1 2024, filed 10 May 2024.